New RA pill shows promise in early trial
NCT ID NCT07377773
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests an experimental drug called QLS12010 in 180 adults with moderate-to-severe rheumatoid arthritis. Participants are randomly assigned to receive different doses of the drug or a placebo for 12 weeks. The main goal is to see if the drug reduces joint swelling and tenderness better than placebo, and to check for side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS (RA) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a simple blood test flag heart risk in rheumatoid arthritis?
- Learning to Self-Care: a new approach to ease RA stiffness?
- Can a specialized hand exercise protocol restore grip and ease pain in rheumatoid arthritis?
- Can less be more? trial tests cutting RA medication doses
- Can a new pill tame rheumatoid arthritis when standard drugs fail?
- Can two common drugs tame rheumatoid arthritis?